StockGlow

CRISPR Therapeutics AG N (1CG.F)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

42.21+0.00%Healthcare
Compare 1CG.F with
StockGlow Score
13
Bearish
BearishBullish
1 year ago-12.1%

The outlook

CRISPR Therapeutics AG N currently reads as bearish based on below its 50- & 200-day averages, 15% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range15% of the way from its 52-week low to high
Market cap
$4.16B
52-wk high
68.50
52-wk low
37.60
50-day avg
45.81
200-day avg
45.87
Trailing P/E
—

Similar stocks

1CG.SGCRISPR Therapeutics AG$41.61-0.86%8EM.FEditas Medicine, Inc.$2.32+3.57%C2RS34.SACRISPR Therapeutics AG$30.45+0.00%1CG.MUCRISPR Therapeutics AG$42.33+1.87%38I.FIntellia Therapeutics, Inc.$9.30+1.53%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy